Shots:
- Osivax reported that the P-IIb (Asuniva) field efficacy trial of OVX836 (480 µg) vs PBO in 2,850 healthy adults aged 18–59yrs. in Europe did not meet its pre-specified 1EP of 50% vaccine efficacy (VE), with a VE point estimate of 24% (not statistically significant)
- 2EPs showed VE point estimates of 28% (CDC-defined influenza-like illness), 27% (A/H3) & 25% (A/H1N1pdm09); OVX836 demonstrated a favorable safety profile consistent with prior trials and induced robust NP-specific antibody & T-cell responses
- Osivax will advance OVX836 in combination with traditional seasonal influenza vaccines in a single injection, enabled by collaborations with GC Biopharma and a second undisclosed global pharma partner; OVX836 is a first-in-class nucleoprotein (NP)-targeting influenza A vaccine candidate based on the oligoDOM technology
Ref: Globenewswire | Image: Osivax | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
